Oppenheimer Keeps a Buy Rating on Voyager Therapeutics (VYGR)
In a report released yesterday, Jay Olson from Oppenheimer maintained a Buy rating on Voyager Therapeutics (VYGR), with a price target of $26.00. The company’s shares closed last Friday at $10.01.
According to TipRanks.com, Olson is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -6.5% and a 37.4% success rate. Olson covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Madrigal Pharmaceuticals, and ACADIA Pharmaceuticals.
Currently, the analyst consensus on Voyager Therapeutics is a Moderate Buy with an average price target of $19.14.
See today’s analyst top recommended stocks >>
The company has a one-year high of $18.80 and a one-year low of $6.26. Currently, Voyager Therapeutics has an average volume of 259.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.
Read More on VYGR: